Of the solid tumor types that metastasize to the brain, melanoma has the highest propensity to form brain metastases. In addition, much remains unknown regarding the pathophysiology involved in melanoma cell extravasation through the bloodbrain barrier, which enables interactions with the microenvironment, and melanoma cell transcriptomic responses to brainspecific cues. However, recent developments in targeted therapy and immunotherapy have generated considerable optimism regarding the treatment of metastatic melanoma. Although robust efficacy data exist on systemic therapy treatment of extracranial melanoma, data in the setting of melanoma brain metastases (MBM) are limited, primarily because patients with MBM are typically excluded from clinical trials. However, several clinical trials focusing on patients with MBM are now complete, and more are underway. Clinical evaluation of serine/threonine-protein kinase B-Raf inhibition in combination with MEK inhibition for MBM produced intracranial response rates of close to 60%, suggesting that inhibition of the mitogen-activated protein kinase pathway has the potential to further improve MBM outcomes. For immunotherapy, there is now increasing evidence that checkpoint inhibitors may also be effective in MBM with a high rate of durable intracranial responses observed with combination therapy. Furthermore, radiotherapy-particularly MBM treatment with mainstay stereotactic radiosurgeryappears to be safe and effective when combined with systemic therapy. Finally, evolving magnetic resonance imaging capabilities have inspired new approaches to the measurement of tumor burden and treatment responses. This review evaluates current published evidence describing MBM as a multifaceted disease and presents an overview of currently available and investigational treatments for patients with MBM.
Introduction
In 2017, an estimated 87 110 new cases of melanoma and 9730 melanoma-related deaths will be reported in the USA, with incidence increasing [1, 2] . Although only %4% of patients present with metastatic disease at diagnosis [1] , these patients face historical long-term survival rates of <10% [3] . New therapies are dramatically changing patient survival, including combined BRAF and MEK inhibition for patients whose tumors harbor a BRAF V600 mutation and immunotherapies such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitors and programmed cell death 1 (PD-1) inhibitors [4] [5] [6] [7] [8] . Long-term remissions are increasingly frequent among responders to immunotherapy, bringing new hope and excitement.
However, melanoma brain metastases (MBM) are an increasingly common clinical challenge. Lung, breast, and melanoma are the most common cancers leading to metastases in the brain [9] ; however, melanoma has the highest propensity [10, 11] . Most patients who develop MBM will die as a direct consequence [10, 11] . A subset of patients will also develop leptomeningeal disease (LMD), which is associated with significant morbidity and a median survival of just weeks [12] .
The need to meaningfully assess therapeutic responses in MBM is critical. To address this, the Response Assessment in Neuro-Oncology (RANO) Working Group proposed a new approach for standardizing assessment of brain metastases (BMs) [13] . This review presents existing and emerging data and provides a framework for future advances in the assessment and treatment of patients with MBM.
Neurotropism: the central nervous system as a preferred niche for metastatic melanoma Considerable effort has been devoted to understanding why the brain is a common site of melanoma metastasis. Whereas Paget originally proposed the widely held 'soil and seed' hypothesis in 1889 [14] , a newer hypothesis proposes that tumor cells might bring stromal components with them from their primary site (bringing their own soil) [15] .
Metastasis to the brain is a multistep process. Primary tumor cells initially enter the circulation and then undergo hematogenous spread until they arrest within capillary beds of organs, where they proliferate and form a metastasis [16] . Parenchymal BMs initiate with metastatic melanoma cells crossing the blood-brain barrier (BBB), which may be facilitated by shared transcriptomic lineage between melanocytes and brain cells and the affinity of melanoma cells for soluble growth factors and cytokines produced within the brain [16] . For example, human melanoma cells express neural cell adhesion molecules (NCAMs), which stimulate tumor cell growth and motility [17] . Under normal conditions, NCAMs are primarily expressed by neurons and glia during embryonic development [18] . Epidermal growth factor receptor ligand HBEGF, cyclooxygenase 2, and the a2,6-sialytransferase ST6GALNAC5 appear to mediate cancer cell migration across the BBB [19] . Activation of integrins such as a v b 3 and b 1 may also control tumor cell arrest and adhesion to brain vasculature [20] . Microglia and astrocytes also support metastatic cell proliferation, and preclinical models indicate that reactive glia create a microenvironment that favors tumor growth. Furthermore, pleckstrin homology domain-containing A5 is expressed at the leading edge of motile cells, and its expression is strongly associated with cancer cell migration [21] .
Blood-brain barrier
The processes by which melanoma cells 'home in' on and penetrate the BBB and the intricacies of reciprocal signaling between MBM and its microenvironment during metastasis remain largely unexplained. As with somatic vasculature, the BBB's innermost layer is composed of endothelial cells that are bound together by tight junction proteins that form gap junctions (Figure 1 ). The second BBB layer is composed of pericytes and glial endfeet [22] . Together, these layers make central nervous system (CNS) blood vessels largely impervious to cells, viruses, and large and/or hydrophilic molecules.
Microscopic imaging studies have documented the steps of MBM formation: chick embryo models revealed that melanoma cells express connexin 26, which is known to regulate direct cellcell communication [23, 24] . Interestingly, connexin 26 mRNA knockdown prevented MBM formation, and injection of the gap junction inhibitor carbenoxolone reduced the number and size of MBM [23] .
Within a blood vessel, melanoma cells initially maintain close vascular contact while proliferating and spreading along its length ( Figure 2 ) [25] . Tumors use multiple mechanisms to ensure an adequate blood supply for brain metastasis growth and proliferation, but expression of vascular endothelial growth factor A (VEGF-A) appears critical. VEGF-A hypersecretion also increases vascular permeability [25] , potentially improving tumor exposure to exogenous therapeutics [16] . Thus, as MBM cells proliferate, the nascent tumor secretes growth factors and cytokines that enhance its fitness while simultaneously compromising the BBB.
Molecular alterations in MBM
BRAF V600E is the most common mutation observed in metastatic melanoma (% 40%-50%), and drives constitutive activation of the mitogen-activated protein kinase (MAPK)-extracellular signal-related protein kinase (ERK) pathway [26, 27] . Paired tissue samples from primary tumors and metastases showed an 80% genetic concordance, which was lower than that between the primary tumor and metastases to the draining lymph node (93%) and visceral organs (96%) [28] . Also, more MBM than primary tumors harbored BRAF (48% versus 43%) or NRAS (23% versus 15%) mutations [28] .
In contrast, Chen et al. assayed 16 paired samples of MBM and extracranial metastases and found that all sample pairs were concordant for BRAF and NRAS mutations and other genetic alterations [29] . Transcriptomic analyses were generally equally concordant; however, several proteomic markers in the phosphoinositide 3-kinase (PI3K) signaling pathway were selectively elevated in MBM samples, including phosphorylated protein kinase B (pAKT) and glycogen synthase kinase 3a/b [29] . Immunohistochemical analyses of paired extracranial and MBM samples confirmed exceptionally high levels of pAKT and loss of tumor suppressor phosphatase and tensin homolog (PTEN) expression in the MBMs [30] . Exposure of melanoma cells to astrocyte-conditioned but not fibroblast-conditioned medium also upregulated pAKT and increased cellular invasiveness [30] . Subsequent research confirmed that melanoma cells lose PTEN expression on exposure to the brain microenvironment [31] . Consistently, astrocytes were shown to secrete exosomes containing microRNA-19a-an epigenetic suppressor of PTEN [31] . These results highlight the complex interactions between melanoma cells and their microenvironment, which facilitate establishment and perpetuation of MBM and clearly identify an MBM process that is potentially targetable with existing agents.
Targeted therapies in the treatment of MBM Mechanistic challenges to targeted therapeutics crossing the BBB Preclinical studies in rodents have shown that concentrations of vemurafenib, dabrafenib, or trametinib were two to three logarithms higher in plasma than brain after intravenous administration, indicating restricted BBB penetrance-likely due efflux transporters in the BBB [32] [33] [34] . Notably, at equal plasma concentration, brain concentration of dabrafenib was significantly higher than that of vemurafenib [32] . However, most mouse disease models have an intact BBB and no intracranial tumors. The presence of BMs is widely recognized to disrupt the BBB and alter permeability of therapeutic agents [16] .
Prospective clinical trials
Recent data have stimulated new research evaluating MBMdirected systemic targeted therapies in ongoing or planned clinical trials (Tables 1 and 2 ). The efficacy of dabrafenib against MBM was first noted in a phase I dose-finding trial in patients with treatment-naive MBM (9/10 patients with intracranial response) [35] . This striking result led to a prospective, open-label, phase II trial (BREAK-MB; NCT01266967) of 172 BRAF mutation-positive patients with !1 MBM. Dabrafenib demonstrated intracranial activity regardless of prior local therapy and was well tolerated [36] . The intracranial overall response rate (ORR) was 35% (49/139) in patients with a BRAF V600E mutation but 15% (5/33) in those with a BRAF V600K mutation [36] . In BRAF V600E-mutated patients with no prior local therapy, the ORR was 38%, median progression-free survival (PFS) was 16.1 weeks, and median overall survival (OS) was 33.1 weeks [36] .
In a phase II study of vemurafenib monotherapy in patients without (n ¼ 90) or with (n ¼ 56) prior treatment of BRAF V600-mutant MBM, median PFS (brain only; 3.7 versus 4.0 months) and OS (8.9 versus 9.6 months) were similar between cohorts [37] . In patients without prior MBM treatment, the intracranial ORR was 18%. This appears to be lower than the ORRs reported from the BREAK-MB trial [36] , although it should be noted that patient eligibility was based on cobas testing, which is sensitive for BRAF V600E but not BRAF V600K. In BREAK-MB, patients with a BRAF V600K mutation had substantially lower ORRs [36] .
The COMBI-MB trial (NCT02039947) is evaluating dabrafenib plus trametinib in patients with MBM and BRAF mutation [38] . Among patients with asymptomatic BRAF V600E-positive MBM, intracranial response was 58% in patients without (44/76) and 56% in patients with (9/16) previous local brain therapy (median follow-up, 8.5 and 20.0 months, respectively) [38] ; median intracranial PFS was 5.6 and 7.2 months, and 6-month OS was 79% and 81%. The fact that PFS in patients with intracranial was almost half that observed in patients with extracranial lesions in large randomized studies (median PFS, 11.0 months [39] ) suggests that intracranial resistance may set in faster secondary either to inadequate MAPK inhibition or to preferential emergence of parallel resistance pathways (e.g. PI3K/AKT) in the brain. Intracranial responses also occurred in patients with BRAF V600D/K/R-positive, asymptomatic MBM (44%) and those with symptomatic MBM (59%). The manageable safety profile was consistent with that in previous studies.
Emerging treatment strategies
Although BRAF inhibitors (BRAFis) produce excellent extracranial responses, MBM may still develop during BRAFi therapy. Melanoma cells can activate ERK in the absence of BRAF stimulation, resulting in a release from inhibition and subsequent disease relapse. Other potential mechanisms of acquired/secondary tumor resistance have been extensively described [40] , including cooperation and compensatory signaling through the MAPK and PI3K pathways when one or the other is inhibited. Factors associated with the brain microenvironment appear to be critical to acquired resistance to BRAFi monotherapy; the addition of cerebrospinal fluid (CSF) to cultured BRAF V600-mutant melanoma cells significantly reduced the ability of BRAFi to block ERK signaling [41] . However, BRAF and PI3K co-inhibition greatly increased efficacy, implicating CSF in PI3K pathway activation [41] .
Combinations of different signaling pathway inhibitors are also under evaluation in a 'parallel inhibition' strategy. Although preclinical reports are promising [42, 43] , increased treatment-related toxicities (e.g. rash, lipase elevation, stomatitis, diarrhea, and fatigue) represent a challenge with this approach [44, 45] . Nonetheless, considering that the brain's microenvironment selectively upregulates the PI3K pathway [29] , designing trials with parallel inhibition of MAPK and PI3K should be a near-term goal of clinical studies.
Immunotherapy in the treatment of MBM Immune checkpoint inhibitors
As with targeted therapy, the introduction of checkpoint inhibitors has had a tremendous impact on the melanoma treatment landscape. Experience with high-dose interleukin (IL) 2 and adoptive cell therapies showed that a patient's immune system can be utilized to achieve anticancer control; the approval of multiple checkpoint inhibitors, including ipilimumab (anti-CTLA-4) and nivolumab and pembrolizumab (anti-PD-1), marked a new era of immunotherapy [46] [47] [48] [49] [50] [51] [52] .
Mechanistic challenges associated with immune cells crossing the BBB
Various mechanisms control immune cell access to the perivascular and parenchymal compartments of the CNS (Figure 3 ). Selectin and/or a 4 -integrin family adhesion molecules mediate initial T-cell contact with the vascular endothelium and arrest on the vessel wall [53] . Once adherent, T cells roll along the surface until they encounter chemotactic signals from the endothelium that induce arrest, expression of a 4 -and b 2 -integrins, and a search for extravasation sites [53, 54] . Cells migrate through the endothelium via transcellular and paracellular pathways mediated by intercellular cell adhesion molecules [55] .
Cytokines in the perivascular compartment can induce immune cells to penetrate the parenchymal basement membrane [56] . Macrophages secrete enzymes to weaken and/or break bonds between astrocytes and the extracellular matrix molecule b-dystroglycan [57] . The dissolution of the extracellular matrix allows T cells to move between astrocytic endfeet to enter the parenchyma. In addition, the brain's sparse lymphatic system provides an alternate route for melanocyte access to the CNS, facilitates melanocyte interaction with sentinel T cells, and gives activated lymphocytes direct access to MBM [58] .
Prospective clinical trials
As with targeted therapies, limited data are available on the efficacy and safety of immunotherapies in patients with MBM. Completed and planned or ongoing trials involving immunotherapy are listed in Tables 3 and 4 Figure 3 . Schematic demonstrating the multistep process for immune cell access to the central nervous system parenchyma. The process is initiated by first contact between a T-cell and the endothelium which is mediated by the selectin family. Once contact is established, the T-cell rolls in the direction of blood flow until signalled to arrest via integrin/cell adhesion molecule interactions. These interactions drive remodelling of the cytoskeleton allowing the T cell to probe for sites of extravasation, which can be transcellular or paracellular. Astrocytic endfeet provide an additional layer of protection at the BBB. However, matrix-metalloproteinases secreted by macrophages within the pericytic compartment can disrupt the association between endfeet and the extracellular matrix, allowing T cells to access the parenchyma. an open-label, phase II trial (NCT00623766) [59] . Immune-related responses (IRRs) were highest in asymptomatic patients who did not require steroids. Per IRR criteria, median PFS in the brain was 1.9 versus 1.2 months and OS was 7.0 versus 3.7 months in asymptomatic versus symptomatic patients who required use of steroids, respectively. The phase II NIBIT-M1 (NCT01654692) study enrolled 86 patients with unresectable stage III or IV cutaneous melanoma. Twenty patients had asymptomatic MBM at baseline and received ipilimumab plus fotemustine [60] . A 3-year follow-up analysis showed median OS of 12.7 and 12.9 months in patients with MBM and for the population overall (N ¼ 86), respectively. The open-label, phase III NIBIT-M2 trial (NCT02460068) is evaluating fotemustine alone, fotemustine plus ipilimumab, or ipilimumab plus nivolumab in patients with asymptomatic MBM [61] . In a single-arm study of pembrolizumab in patients with lung or melanoma BMs, 18 MBM patients were treated and 4 achieved durable responses, although the rate of neurologic toxicity was 17% [62] .
Nivolumab plus ipilimumab combination therapy is also being evaluated in patients with asymptomatic MBM. At a median follow-up of 9.2 months in the CheckMate-204 study (N ¼ 75), the intracranial ORR was 55% and the complete response rate was 21%, with intracranial and extracranial responses largely concordant [63] . Responses were ongoing in 38 of 41 patients, and the 6-month PFS was 67%. Treatment-related grade 3/4 adverse events (AEs) occurred in 52% of patients (8% with a nervous system AE), 25% of patients discontinued due to a treatment-related grade 3/4 AE, and 1 patient died of immune-related myocarditis. These results suggest that, similar to extracranial responses, intracranial responses to immunotherapy can be profound and durable.
The Anti-PD1 Brain Collaboration trial (NCT02374242), which is evaluating nivolumab plus ipilimumab versus nivolumab alone in patients (N ¼ 79) with MBM, showed IRRs of 46% (combination, n ¼ 35) and 20% (nivolumab, n ¼ 25) among asymptomatic patients with no prior local radiotherapy and 6% (nivolumab, n ¼ 16) among patients with failure on local therapy, symptomatic disease, and/or LMD [64] . For asymptomatic patients with no prior drug treatment versus prior BRAFi plus MEKi treatment, intracranial responses were 56% versus 13% with combination treatment and 21% versus 17% with nivolumab alone. This potentially suggests decreased intracranial clinical activity, particularly in patients treated with nivolumab plus ipilimumab, following treatment with a BRAFi plus MEKi; however, patient number was limited and further investigation is warranted. Treatment-related grade 3/4 AEs occurred in 54% (combination) and 15% (nivolumab) of patients, and 26% and 5% of patients, respectively, discontinued due to an AE. Co-administration of low-dose BRAFi with an anti-PD-1 antibody in a xenograft tumor mouse model enhanced the efficacy achieved with each drug alone. In addition, combined BRAFi þ anti-PD-1 treatment increased xenograft-infiltrating CD3þ T cells 7.5-fold versus either monotherapy [65] . These data suggest targeted therapy might increase melanoma immunogenicity, possibly by increasing melanocyte differentiation antigen expression [66, 67] . This hypothesis was tested by collecting serial biopsy specimens from a patient with cutaneous melanoma treated with vemurafenib followed by ipilimumab [65] . The number of CD8þ cells initially increased with vemurafenib treatment; however, this immune infiltration was transient, and decreased to pretreatment levels within 5 weeks despite continuous treatment. Initiation of ipilimumab increased CD8þ values to levels initially obtained with vemurafenib. However, the combination of vemurafenib and ipilimumab caused dose-limiting liver function abnormalities, leading to early termination of a phase II study (NCT01673854) [68] . Additional trials evaluating immunotherapy plus targeted therapy combinations are ongoing (NCT01656642, NCT01940809, NCT02130466) [69] [70] [71] . Our ongoing study of nivolumab þ dabrafenib and/or trametinib is one of the first triplet combination studies to allow enrollment of patients with MBM as well as LMD (NCT02910700) [72] .
Treatment of LMD
In patients with melanoma, LMD is associated with the worst OS, with survival generally reported in weeks [12] . No standard of care exists, and the current National Comprehensive Cancer Network guidelines recommend only supportive care and radiation to reduce bulky disease at symptomatic sites [73] . Furthermore, patients with LMD are almost always excluded from clinical trials. Systemic chemotherapy does not appear to provide benefit for metastatic melanoma with LMD, and a prospective clinical trial (n ¼ 9) using a combination of intrathecal (IT) and systemic therapy reported a median OS of only 8 weeks, with 2 patients deriving longer clinical benefit [74, 75] . Recent retrospective analyses of patients with melanoma and LMD suggest that targeted therapy and immunotherapy might improve patient outcomes [76, 77] , and clinical trials using a systemic approach are ongoing (NCT02939300). IL-2 can penetrate the BBB from the circulation into the CSF and vice versa; however, its elimination halfway is much longer if given intrathecally [78, 79] . Administration of IT IL-2 results in a rapid increase of neutrophils (followed by sustained lymphocytosis) and cytokines in the CSF [80] . This observation was the basis for the IT IL-2 program at The University of Texas MD Anderson Cancer Center, which has treated >120 patients to date with this approach. The analysis of a contemporary series of 43 consecutive patients with melanoma-associated LMD treated with IT IL-2 between 2006 and 2014 showed 1-, 2-, and 5-year survival rates of 36%, 26%, and 13%, respectively [81] . Although these results are encouraging and support further clinical assessment in this population, toxicities are limiting and IL-2 is not a standard therapy in this setting and has never been compared directly with modern therapies; therefore, data from prospective clinical trials are needed to confirm these outcomes. The results of an ongoing clinical trial using IT anti-PD-1 are eagerly awaited (NCT03025256).
Radiation therapy modalities and MBM
Although whole-brain radiotherapy (WBRT) was historically a mainstay of treatment of patients with MBM, its use is mainly palliative today [82, 83] . As survival with primary CNS cancer and MBM has increased, the effects of radiotherapy on cognition have come into focus [84] . A systematic review concluded that WBRT can profoundly impair cognition and, in some cases, leads to irreversible neurocognitive impairment [85] . Stereotactic radiosurgery (SRS) can mitigate many of the negative cognitive effects of WBRT and/or conformal-field WBRT [86] , producing 12-month local control rates up to 75% [87, 88] . Furthermore, patients who received WBRT and the N-methyl-D-aspartate receptor antagonist memantine had better cognitive function over time, including a significantly longer time to decrease in cognitive function (P ¼ 0.01) and delayed decreases in memory, executive function, and processing speed [84] .
Radiation necrosis (RN) is observed more often with SRS than with other radiation modalities, with an incidence of 9%-19% among patients with BMs treated with SRS [89] [90] [91] . RN onset typically occurs 7-12 months after radiation and can be associated with significant morbidity, including psychomotor slowing, seizures, and sensorimotor deficits. The CNS immune system has emerged as a main driver of RN development. In the brain, radiation exposure can increase expression of inflammatory cytokines (e.g. IL-1a, IL-6), tumor necrosis factor a, and VEGF [92] , potentially causing progressive BBB dysfunction and edema.
No prospectively collected data are currently available to evaluate the effect of targeted therapy or immunotherapy on RN incidence. A retrospective review of 54 patients receiving SRS showed no difference in RN incidence between patients did or did not receive ipilimumab within 4 months of SRS. Furthermore, no substantial difference in 1-year OS (37% versus 39%) was observed [93] . Case reports have described RN after the use of CTLA-4 blockade and SRS [94, 95] . A recent chart review of consecutively treated patients who received SRS plus systemic therapy (N ¼ 180) showed that RN incidence significantly increased in patients who received radiation plus immunotherapy versus chemotherapy or targeted therapy (odds ratio 2.40; P ¼ 0.03) [96] . Conversely, chemotherapy was associated with a lower risk of RN relative to other treatments (odds ratio 0.38; P ¼ 0.01). Interestingly, median OS was significantly longer in patients who developed RN than in patients without RN (23.7 versus 9.9 months, respectively; P ¼ 0.01).
An increased RN incidence may also be associated with BRAFi and SRS, although available data are conflicting [96] . Among 15 patients treated with targeted therapy either before, concurrent with, or after SRS, 1-year OS (64.3% versus 40.4%; P ¼ 0.205), local failure (3.3% versus 9.6%), and distant intracranial failure (63.9% versus 65.1%) were similar between SRS þ BRAFi versus SRS alone. However, higher rates of radiographic RN (22.2% versus 11.0% at 1 year; P < 0.001) and symptomatic RN (28.2% versus 11.1% at 1 year; P < 0.001) occurred with BRAFi þ SRS versus SRS alone [97] .
Given increased use of these treatment modalities, clinicians should be aware of delayed and potential toxicities. Prospective clinical trials are needed to describe the true incidence of RN versus SRS alone.
Targeted therapy in combination with SRS
SRS can effectively lead to local control of MBM, but its use is limited by the number of MBM [98] . This issue is being investigated in an open-label phase II study (NCT02974803) of concurrent dabrafenib and trametinib with SRS in the management of patients with BRAF mutation-positive melanoma and 1-10 MBM [99] . Of note, the Eastern Cooperative Oncology Group has published guidelines on avoiding severe toxicity secondary to BRAFi and radiation treatment [100] .
Immunotherapy in combination with radiation
In a retrospective study of 77 patients with MBM, patients who received ipilimumab plus SRS achieved a longer median survival (21.3 versus 4.9 months) than those who received radiotherapy alone [101] . Another retrospective chart review of 70 patients treated from 2005 to 2012 compared the efficacy of SRS or WBRT with or without ipilimumab. Among ipilimumab-treated patients, 39.4% received prior or subsequent BRAFi therapy. Ipilimumab did not significantly improve survival in the WBRT subset (HR 0.56, P ¼ 0.15). However, the addition of ipilimumab to SRS radiation improved survival compared with SRS alone (median 19.9 versus 4.0 months; P ¼ 0.009), with no increase in toxicity [102] . Median OS was similar between patients with stage IV melanoma with or without MBM treated with SRS and ipilimumab (29.3 and 33.1 months, respectively) [103] .
Identification and quantification of MBM
Accurate measurement of BMs is critical to assessing extent of disease and therapeutic efficacy. However, no consensus on how best to measure these tumors or interpret results of imaging studies and no clear standards for assessing treatment efficacy exist. Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria were developed to assess extracranial disease, and both the MacDonald criteria and RANO for high-grade gliomas are limited in assessing MBM [104] [105] [106] . Table 5 lists the current measurement criteria, their major characteristics, and limitations.
The inability to differentiate treatment-related changes from disease progression is a major limitation, and interrater discrepancies can be high. In the BREAK-MB trial [36] , RECIST v1.1 was modified to address this issue, resulting in an interesting discrepancy between investigators and central radiologic review that highlights the difficulty of assessing intracranial response. The primary end point was investigator-assessed ORR per modified RECIST v1.1, but establishment of an adjudication committee was required after a central panel of radiology reviewers disagreed with investigators in 42% of cases. The adjudication committee sided with the investigators 68% of the time.
To maintain methodologic uniformity across trials, the RANO Brain Metastases (RANO-BM) Working Group proposed assessment criteria using a single linear measurement [107] . By focusing and guiding assessment of lesions solely in the parenchyma, RANO-BM criteria should complement RECIST. However, as improved imaging techniques become available, the RANO-BM criteria may need modification. More recently, RANO LMD and immunotherapy criteria were also published to address the need for standardization in patients with LMD and those receiving immunotherapy [108, 109] .
Future directions and conclusions
Development of MBM remains a major challenge. Basic research into the mechanisms by which melanoma cells penetrate the BBB and metastasize in the parenchyma has advanced our understanding of how brain-tumor cross-talk supports and promotes MBM growth. These advances have also revealed promising targets for therapeutic intervention. BRAFi þ MEKi and immunotherapy are demonstrating improved clinical outcomes in this difficult-to-treat population. Targeted therapy, immunotherapy, and radiotherapy combinations may provide longer disease-free intervals and OS. Every effort should be made to extend the therapeutic benefit of systemic agents to patients with MBM by including this population in randomized trials of novel treatments.
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